Stroke: Covidien wins Canadian OK for its Solitaire revascularization device

Thu, 12/13/2012 - 4:48pm
Mass Device

Health Canada approves Covidien's to Solitaire revascularization device for restoring blood flow to the brain in patients with acute ischemic stroke.

Covidien logo

Medtech giant Covidien (NYSE:COV) won Health Canada approval for its Solitaire FR revascularization device, intended to remove blood clots and restore blood flow in the brains of patients suffering acute ischemic stroke.

"Stroke is a widespread public health issue, with approximately 50,000 Canadians experiencing a stroke annually," president of vascular therapies Stacy Enxing Seng said in prepared remarks. "Solitaire FR is intended to transform the way this potentially fatal and often debilitating condition is treated."


Share this Story

You may login with either your assigned username or your e-mail address.
The password field is case sensitive.